In terms of clinical stages, we discovered that the expression levels of multiple TLR family members, including TLR3, TLR4, TLR8, TLR10, and TLR8-AS1, were significantly different between stage I and IV of BRCA, COAD, HNSC, and STAD (Figure S1), implying the involvement of the TLR family in tumour progression mechanisms, which may have implications for diagnosis and clinical risk prediction. Here, TLR3 is linked to neoplasm.